Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label retreatment with Aclasta in relapsed Paget's disease of bone
2008-002898-12Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in Paget's disease of bone, sponsored by Novartis. Primary endpoint: Normalization of total serum alkaline phosphatase within 6 months. Started Aug 2008; status: completed.
02
Drugs
zoledronic acid
03
Conditions
Paget's disease of bone
Beyond the preview
Go deeper on 2008-002898-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002898-12.